Eli Lilly

Showing 15 posts of 202 posts found.


Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data

July 31, 2019
Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma

Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …


Lilly’s Baqsimi nasal powder gains FDA approval after proving non-inferior to injection

July 25, 2019
Sales and Marketing Baqsimi, Eli Lilly, FDA, US, diabetes, pharma

Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, …

US Judge blocks Trump administration law requiring pharma to include prices in TV ads

July 9, 2019
Manufacturing and Production Amgen, Eli Lilly, MSD, TV ads, Trump, USA, court, pharma

A judge has blocked the Trump administration from enacting a law that would require pharmaceutical companies to include the prices …


Drugmakers sue Trump over prices in TV ads

June 17, 2019
Sales and Marketing Amgen, Eli Lilly, HHS, MSD, Merck, Trump, pharma

Amgen, Eli Lilly and MSD have sued the Trump administration to try and block measures to force pharma companies to …


Eli Lilly’s heart drug underwhelms with REWIND trial

June 11, 2019
Manufacturing and Production Eli Lilly, Trulicity, pharma

Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according …


Eli Lilly’s Emgality approved in the US for episodic cluster headache

June 5, 2019
Research and Development, Sales and Marketing Eli Lilly, Emgality, episodic cluster headache, migraine, pharma

Eli Lilly’s Emgality (galcanezumab-gnlm) self-administered injection solution has secured approval in the US for the treatment of episodic cluster headache, …


Japan’s health ministry warns of serious side effects of Lilly’s Verzenio

May 23, 2019
Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma

Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …


Lilly’s Cyramza approved in US for hepatocellular carcinoma sub-population

May 13, 2019
Sales and Marketing Eli Lilly, FDA, cyramza, hepatocellular carcinoma, pharma

Eli Lilly’s vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a …


Top Ten most popular articles on Pharmafile.com this week!

May 10, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, GSK, Innoviva, NHS, Novartis, health, migraine, pharma

This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving …


Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine

May 8, 2019
Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …


Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure

April 26, 2019
Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma

Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …


Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment

March 13, 2019
Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma

Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …


Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients

February 15, 2019
Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …


Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials

February 5, 2019
Manufacturing and Production, Research and Development Eli Lilly, Olumiant, atopic dermatitis, pharma

Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). …

Latest content